(Q37988252)

26 August 2017

Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis (English)

1 reference

26 August 2017

1 reference

1

1 reference

PubMed ID

22366288

26 August 2017

language of work or name

English

0 references

publication date

15 February 2012

1 reference

Experimental Cell Research

26 August 2017

1 reference

26 August 2017

318

1 reference

26 August 2017

11

1 reference

26 August 2017

1208-1212

1 reference

Tumor resistance to apoptosis

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Anticancer activities of histone deacetylase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Histone modifications: signalling receptors and potential elements of a heritable epigenetic code

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Modulation of TRAIL-induced apoptosis by HDAC inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Targeting the extrinsic apoptosis pathway in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Targeting mitochondria for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Mitochondrial membrane permeabilization in cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Targeting IAP proteins for therapeutic intervention in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2012.02.005

10.1016/J.YEXCR.2012.02.005

7 January 2021

Identifiers

DOI

1 reference

release_e55ieoqerzc33d4tb2htxvcw3a

26 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/e55ieoqerzc33d4tb2htxvcw3a

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

22366288

1 reference

PubMed ID

22366288